Brescia-COVID Respiratory Severity Scale (BRCSS) and Quick SOFA (qSOFA) score are most useful in showing severity in COVID-19 patients.
Adult
Aged
Area Under Curve
COVID-19
/ diagnosis
Coinfection
/ diagnosis
Female
Hospital Mortality
Humans
Intensive Care Units
Lymphocytosis
Male
Middle Aged
Observer Variation
Organ Dysfunction Scores
Patient Admission
Predictive Value of Tests
Prognosis
Regression Analysis
Respiration
Respiration Disorders
Risk Factors
SARS-CoV-2
Severity of Illness Index
Smoking
Treatment Outcome
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 11 2021
08 11 2021
Historique:
received:
25
03
2021
accepted:
28
09
2021
entrez:
9
11
2021
pubmed:
10
11
2021
medline:
30
11
2021
Statut:
epublish
Résumé
In this study, we compare the predictive value of clinical scoring systems that are already in use in patients with Coronavirus disease 2019 (COVID-19), including the Brescia-COVID Respiratory Severity Scale (BCRSS), Quick SOFA (qSOFA), Sequential Organ Failure Assessment (SOFA), Multilobular infiltration, hypo-Lymphocytosis, Bacterial coinfection, Smoking history, hyper-Tension, and Age (MuLBSTA) and scoring system for reactive hemophagocytic syndrome (HScore), for determining the severity of the disease. Our aim in this study is to determine which scoring system is most useful in determining disease severity and to guide clinicians. We classified the patients into two groups according to the stage of the disease (severe and non-severe) and adopted interim guidance of the World Health Organization. Severe cases were divided into a group of surviving patients and a deceased group according to the prognosis. According to admission values, the BCRSS, qSOFA, SOFA, MuLBSTA, and HScore were evaluated at admission using the worst parameters available in the first 24 h. Of the 417 patients included in our study, 46 (11%) were in the severe group, while 371 (89%) were in the non-severe group. Of these 417 patients, 230 (55.2%) were men. The median (IQR) age of all patients was 44 (25) years. In multivariate logistic regression analyses, BRCSS in the highest tertile (HR 6.1, 95% CI 2.105-17.674, p = 0.001) was determined as an independent predictor of severe disease in cases of COVID-19. In multivariate analyses, qSOFA was also found to be an independent predictor of severe COVID-19 (HR 4.757, 95% CI 1.438-15.730, p = 0.011). The area under the curve (AUC) of the BRCSS, qSOFA, SOFA, MuLBSTA, and HScore was 0.977, 0.961, 0.958, 0.860, and 0.698, respectively. Calculation of the BRCSS and qSOFA at the time of hospital admission can predict critical clinical outcomes in patients with COVID-19, and their predictive value is superior to that of HScore, MuLBSTA, and SOFA. Our prediction is that early interventions for high-risk patients, with early identification of high-risk group using BRCSS and qSOFA, may improve clinical outcomes in COVID-19.
Identifiants
pubmed: 34750412
doi: 10.1038/s41598-021-01181-x
pii: 10.1038/s41598-021-01181-x
pmc: PMC8575935
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21807Informations de copyright
© 2021. The Author(s).
Références
Ann Intensive Care. 2020 Apr 19;10(1):43
pubmed: 32307609
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Pol Arch Intern Med. 2020 May 29;130(5):390-399
pubmed: 32329978
J Autoimmun. 2020 Nov;114:102523
pubmed: 32690352
Transplant Proc. 2020 Oct;52(8):2382-2387
pubmed: 32571705
Front Microbiol. 2019 Dec 03;10:2752
pubmed: 31849894
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
Ann Intensive Care. 2020 Jul 31;10(1):99
pubmed: 32737627
Crit Care. 2010;14(2):207
pubmed: 20392287
Rheumatol Int. 2021 Jan;41(1):7-18
pubmed: 32588191
Risk Manag Healthc Policy. 2020 Jul 20;13:833-845
pubmed: 32765138
World J Pediatr. 2020 Jun;16(3):232-239
pubmed: 32333248
Ann Rheum Dis. 2020 Sep;79(9):1152-1155
pubmed: 32719039
EBioMedicine. 2020 Jul;57:102880
pubmed: 32645614
J Korean Med Sci. 2020 Jun 29;35(25):e234
pubmed: 32597046
Infez Med. 2020 Ahead of print Jun 1;28(2):143-152
pubmed: 32275256
J Clin Lab Anal. 2020 Oct;34(10):e23475
pubmed: 32681559
Clin Exp Rheumatol. 1993 Jul-Aug;11(4):451-6
pubmed: 8403593
Autoimmun Rev. 2020 Jul;19(7):102568
pubmed: 32376398
EClinicalMedicine. 2020 Jul 04;24:100448
pubmed: 32766546
Lancet. 2020 May 16;395(10236):e83
pubmed: 32423585
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Crit Care Med. 2011 Jan;39(1):163-9
pubmed: 20838329
JAMA. 2017 Jan 17;317(3):301-308
pubmed: 28114554
Infect Dis (Lond). 2020 Sep;52(9):666-668
pubmed: 32543300
Scand J Rheumatol. 2017 Jan;46(1):44-48
pubmed: 27359073
Acta Anaesthesiol Scand. 2008 Apr;52(4):467-78
pubmed: 18339152
J Crit Care. 2020 Aug;58:29-33
pubmed: 32330817
Indian Pediatr. 2020 Sep 15;57(9):827-833
pubmed: 32583809
Arthritis Rheumatol. 2014 Sep;66(9):2613-20
pubmed: 24782338
Intern Emerg Med. 2018 Apr;13(3):405-412
pubmed: 28188577
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
JAMA. 2016 Feb 23;315(8):762-74
pubmed: 26903335
JAMA. 2001 Oct 10;286(14):1754-8
pubmed: 11594901
Br J Haematol. 2020 Sep;190(5):e283-e285
pubmed: 32526046
J Med Virol. 2021 Mar;93(3):1532-1537
pubmed: 32860431